Watch AIM. Know when insiders buy.
One email the day a filing lands. Free.
AIM
AIM ImmunoTech Inc.
0.17
+0.00 +0.00%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
78
PASS · insiders 56, shorts 100
Insiders, 90 days
+$13K
net buying · 4 buys, 0 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $5.2MP/E 17.0DIV YIELD —FCF YIELD —REV TTM $95K −21.5%NET INCOME −$14.3MNET CASH $6.3M52W 0.16 – 2.68SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $26K | +4.0% | — | −$3.5M | −$3.8M | — | -0.43 | −$4.6M | — | — | Aug 7 |
| Q1 2026 · Mar 31 | $22K | +37.5% | — | −$2.2M | −$3M | — | -0.69 | −$2.7M | — | — | Aug 7 |
| Q4 2025 · Dec 31derived | $21K | −53.3% | — | −$3M | −$4.2M | — | -0.44 | −$2M | — | — | Mar 27 |
| Q3 2025 · Sep 30 | $26K | −25.7% | — | −$2.4M | −$3.3M | — | 1.57 | −$5.1M | — | — | Nov 17 |
| Q2 2025 · Jun 30 | $25K | −50.0% | — | −$2.6M | −$2.8M | — | -3.68 | −$1.5M | — | — | Aug 7 |
| Q1 2025 · Mar 31 | $16K | −60.0% | — | −$3.6M | −$3.7M | — | -0.05 | −$2.4M | — | — | Aug 7 |
| Q4 2024 · Dec 31derived | $45K | −30.8% | — | −$5.9M | −$6M | — | -9.92 | −$4M | $0 | −$4M | Mar 27 |
| Q3 2024 · Sep 30 | $35K | −23.9% | — | −$4.5M | −$3.7M | — | -6.00 | −$3.1M | — | — | Nov 17 |
| Q2 2024 · Jun 30 | $50K | — | — | −$3.7M | −$1.8M | — | -3.00 | −$3M | — | — | Nov 17 |
| Q1 2024 · Mar 31 | $40K | — | — | −$5.7M | −$5.8M | — | -0.12 | −$4.8M | — | — | Nov 17 |
| Q4 2023 · Dec 31derived | $65K | — | — | −$14M | −$12.6M | — | -0.26 | −$9.8M | — | — | Mar 27 |
| Q3 2023 · Sep 30 | $46K | — | — | −$8.2M | −$7.8M | — | -0.16 | −$5.7M | — | — | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $88K | — | −$11.7M | −$14M | -15861.4% | -8.62 | −$11M | — | — | — | — |
| FY2024 · to Dec 31 | $170K | — | −$19.8M | −$17.3M | -10188.2% | -30.92 | −$14.9M | $18K | −$14.9M | — | — |
| FY2023 · to Dec 31 | $202K | — | −$31.9M | −$29M | -14337.6% | -0.60 | −$21.3M | — | — | — | — |
| FY2022 · to Dec 31 | $141K | — | −$19.9M | −$19.4M | -13790.8% | -0.40 | −$16.1M | $86K | −$16.2M | — | — |
| FY2021 · to Dec 31 | $135K | — | −$18.8M | −$19.1M | -14168.1% | -0.40 | −$14M | $41K | −$14M | — | — |
| FY2020 · to Dec 31 | $163K | — | −$15.2M | −$14.4M | -8834.4% | -0.45 | −$10.4M | $22K | −$10.4M | — | — |
Every number comes from AIM ImmunoTech Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.